Work

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-013-0062-5

Authors: Carolyn D. Britten, Alex A. Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen Pierce, Zev A. Wainberg, Patricia M. LoRusso

Institutions: University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Roswell Park Comprehensive Cancer Center, Pfizer (United States), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2739639286

FWCI: 4.151

Cites: 26

Cited by: 78

Related to: 10